Primary intratesticular leiomyosarcoma

Shunsuke Yoshimine, MD;*, Hidaka Kono, MD;* Ken Nakagawa, MD;* Eiji Kikuchi, MD;* Akira Miyajima, MD;* Kaori Kameyama, MD;† Makio Mukai, MD;† Mototsugu Oya, MD*

Abstract
This report presents a case of primary intratesticular leiomyosarcoma. A 73-year-old male presented with a 6-year history of left scrotal swelling. A radiological examination revealed a left testicular tumour with multiple metastases in the lung, para-aortic lymph node and other organs. A radical orchietomy was carried out and the pathology revealed an intratesticular leiomyosarcoma. The patient received additional chemotherapy. Cases of primary intratesticular leiomyosarcoma are rare. This is, to the best of our knowledge, only the tenth case of leiomyosarcoma in an adult reported in the literature, and the first case involving multiple metastases.

Can Urol Assoc J 2009;3(6):E74-E76

Introduction
Leiomyosarcomas are malignant soft-tissue tumours arising from any tissues containing smooth muscles. However, cases arising in testicular tissue are extremely rare and only 9 cases in adults have been reported so far. Metastatic patients have not been reported. This report presents the first case of an intratesticular leiomyosarcoma with multiple metastases.

Case Report
A 73-year-old male patient visited our hospital with a 6-year history of a left scrotal mass. He had no significant past medical history. A physical examination revealed a left scrotal mass and several palpable subcutaneous nodules ranging from 1 cm to 4 cm in diameter on the chest and abdomen, suggesting subcutaneous metastatic lesions. Lactate dehydrogenase (LDH) and α-fetoprotein (AFP) levels were within the normal ranges, whereas human chorionic gonadotropin-β (HCG-β) was slightly elevated at 0.3 ng/mL (normal range: <0.1 ng/mL). An ultrasonographic examination of the left testis showed a solid mass with hypoechoic and hyperechoic components. Computed tomography scan revealed a left scrotal mass (Fig. 1a), and metastases to the lung (Fig. 1b), para-aortic lymph node, spleen, muscle, subcutaneous tissue and vertebral bone.

The patient underwent a left radical orchietomy. Macroscopically, the tumour was a well-encapsulated whitish to yellowish solid mass with hemorrhage and necrosis (Fig. 2). There was no invasion to the spermatic cord or tunica vaginalis. The weight of the tumour was 1570 g and the size was approximately 20 × 18 × 14 cm. Microscopic examination showed a high degree of cellular proliferation composed of spindle cells with round or oval-shaped nuclei implicating a storiform growth pattern (Fig. 3a). There were more than 2 mitoses per high-power field. Necrosis was evident. Some marked pleomorphic tumour cells with multinucleated giant cells were observed. Immunohistochemical examination revealed that the tumour cells were strongly positive for smooth muscle actin and desmin (Fig. 3b), but negative for S-100 and myogenic regulatory protein (MyoD1) proteins. The pathological diagnosis was leiomyosarcoma.

The patient received additional CYVADIC (cyclophosphamide, vincristine, adriamycin, dacarvazine) chemotherapy. There was no progression of the metastatic lesions as of 9 months after the operation.

Discussion
Intratesticular leiomyosarcoma is an extremely rare tumour and only 9 cases have been reported in adults (Table 1).1-8 Only one case was reported in an infant.9 The age of the patients ranged between 30 and 76, with a mean age of 50.2. Six patients had a right-side tumour, while 3 had a left-side tumour. A radical orchietomy was carried out in all patients, while one patient underwent an orchietomy and a retroperitoneal lymph node dissection that revealed a negative lymph node. One patient died of lung metastasis 14 months after the orchietomy.

All of these cases were assessed as clinical stage-I tumours, as all of the testicular leiomyosarcomas were diagnosed as a local disease, easily recognized and slow-growing. Based on these findings, no adjuvant treatment was administered in these patients.8 Eight patients achieved tumour-free survival
Primary intratesticular leiomyosarcoma

during the course of observation. Therefore, it is still controversial as to whether adjuvant therapy is needed for such cases.

The true etiology of testicular leiomyosarcoma is unknown; however, risk factors have been reported in 3 patients: the use of high-dose anabolic steroids (Case 5),4 chronic inflammation of the testes (Case 7)5 and testicular field radiation for the treatment of leukemia (Case 9).7

The present case was the first case assessed as clinical stage-III. The patient had no obvious past medical history or risk factors; however, it is possible that the metastases had progressed because the testicular tumor had been left untreated for 6 years.

All the tumor markers (AFP, HCG-β and LDH) used in the previously reported cases were within the normal range. In the present case, HCG-β was slightly elevated to 0.3 ng/mL before the operation. Metastatic tumors persisted in several organs in our patient; nonetheless, HCG-β was normalized after the operation. The validity of these 3 tumor markers for testicular leiomyosarcoma, in particular for the evaluation of metastatic disease, is limited.

Based on a review of the literature, the treatment for an intratesticular leiomyosarcoma is a radical orchiectomy and surveillance followed by radiological examination in cases at stage-I. There are no available data regarding the management of stage-II or stage-III tumors. Radiation therapy is not effective for a leiomyosarcoma; therefore, additional chemotherapy is required in advanced cases.

Recently, either gemcitabine or docetaxel has been used as chemotherapy for metastatic uterine leiomyosarcomas, with high objective response rates.10 In the urological field, it is necessary to consider the use of new agents for a metastatic testicular leiomyosarcoma. Taken together, further clinical investigation is required for establishing treatment for an intratesticular leiomyosarcoma.

Conclusion

We experienced an extremely rare case of stage-III primary intratesticular leiomyosarcoma in which a left radical orchiectomy was performed and additional chemotherapy was administered to the metastatic lesions.

*From the Department of Urology, †Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan

Competing interests: None declared.

This paper has been peer-reviewed.

References

Table 1. Summary of the 9 published case reports

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Authors</th>
<th>Age</th>
<th>Side</th>
<th>Clinical stage</th>
<th>Treatment</th>
<th>Follow-up (months)</th>
<th>Outcome</th>
<th>Risk factors</th>
<th>Levels of tumour markers</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yachida1</td>
<td>55</td>
<td>R</td>
<td>I</td>
<td>orchiectomy</td>
<td>24</td>
<td>survived</td>
<td>–</td>
<td>normal</td>
</tr>
<tr>
<td>2</td>
<td>Pellice2</td>
<td>37</td>
<td>L</td>
<td>I</td>
<td>orchiectomy</td>
<td>24</td>
<td>survived</td>
<td>–</td>
<td>normal</td>
</tr>
<tr>
<td>3</td>
<td>Washecka3</td>
<td>47</td>
<td>R</td>
<td>I</td>
<td>orchiectomy</td>
<td>49</td>
<td>survived</td>
<td>–</td>
<td>normal</td>
</tr>
<tr>
<td>4</td>
<td>Washecka3</td>
<td>40</td>
<td>R</td>
<td>I</td>
<td>orchiectomy</td>
<td>42</td>
<td>survived</td>
<td>–</td>
<td>normal</td>
</tr>
<tr>
<td>5</td>
<td>Froehner4</td>
<td>32</td>
<td>R</td>
<td>I</td>
<td>orchiectomy + RPLND</td>
<td>79</td>
<td>survived</td>
<td>anabolic steroid</td>
<td>unknown</td>
</tr>
<tr>
<td>6</td>
<td>Haichi5</td>
<td>70</td>
<td>L</td>
<td>I</td>
<td>orchiectomy</td>
<td>14</td>
<td>death (lung metastases)</td>
<td>–</td>
<td>normal</td>
</tr>
<tr>
<td>7</td>
<td>Ali6</td>
<td>65</td>
<td>R</td>
<td>I</td>
<td>orchiectomy</td>
<td>12</td>
<td>survived</td>
<td>chronic inflammation</td>
<td>normal</td>
</tr>
<tr>
<td>8</td>
<td>Takizawa8</td>
<td>76</td>
<td>L</td>
<td>I</td>
<td>orchiectomy</td>
<td>12</td>
<td>survived</td>
<td>–</td>
<td>normal</td>
</tr>
<tr>
<td>9</td>
<td>Canales7</td>
<td>30</td>
<td>R</td>
<td>I</td>
<td>orchiectomy</td>
<td>6</td>
<td>survived</td>
<td>radiation</td>
<td>unknown</td>
</tr>
<tr>
<td>Current case</td>
<td></td>
<td>73</td>
<td>L</td>
<td>III</td>
<td>orchiectomy+ chemotherapy</td>
<td>9</td>
<td>survived</td>
<td>slightly elevated</td>
<td>normal</td>
</tr>
</tbody>
</table>

R = right; L = left; RPLND = retroperitoneal lymph node dissection.